High Intermediate Risk (HIR) Features in Early Stage Endometrial Carcinoma (EC)
Received Date: May 20, 2022 / Accepted Date: Jun 18, 2022 / Published Date: Jun 20, 2022
Abstract
Statin usage has been shown to reduce the incidence and increase survival of gynecologic malignancies, although its effect on endometrial carcinoma (EC) is still unclear. Our main goal is to look at statin usage and its correlation with early-stage EC characteristics associated with high intermediate risk (HIR). Our hypothesis is that statin-taking women who have early-stage EC have less aggressive pathology at the time of hysterectomy. Our secondary goal is to find out whether using bisphosphonates, NSAIDs, and metformin concurrently may lower the chance of developing HIR early stage EC. These drugs all have anti-cancer properties.
Keywords: Endometrial cancer; Gynecologic cancer; Hypertension; Metabolic syndrome
Citation: Feleke Z (2022) High Intermediate Risk (HIR) Features in Early Stage Endometrial Carcinoma (EC). Int J Inflam Cancer Integr Ther, 9: 193. Doi: 10.4172/2381-8727.1000193
Copyright: © 2022 Feleke Z. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
Open Access Journals
Article Tools
Article Usage
- Total views: 891
- [From(publication date): 0-2022 - Apr 30, 2024]
- Breakdown by view type
- HTML page views: 726
- PDF downloads: 165
